Psychedelics Investing Awakn Life Sciences' Phase III Trial to Be Delivered in the UK National Health Service
Psychedelics Investing Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York
Psychedelics Investing Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis Technology to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program
Psychedelics Investing Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program
Psychedelics Investing Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada
Psychedelics Investing  Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space
Psychedelics Investing Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist
Psychedelics Investing Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs
Psychedelics Investing Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program - Ketamine-Assisted Therapy for Alcohol Use Disorder
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Blue Sky Uranium Increases and Closes 2nd and Final Tranche of the Oversubscribed Non-Brokered Private Placement
